trigram | freq |
---|---|
abdominal aortic aneurysm | 2 |
abnormal uterine bleeding | 2 |
about risks benefits | 2 |
above agents used | 4 |
absence contraindications anticoagulation | 3 |
accelerated radiation therapy | 2 |
account individual'advocate carer | 2 |
acinetobacter species sensitive | 3 |
active against mrsa | 2 |
activity against aeruginosa | 2 |
activity part properly | 2 |
acute coronary syndrome | 3 |
acute myocardial infarction | 2 |
acute treatment migraine | 2 |
addition considered persistently | 2 |
additional risk factor | 3 |
adefovir dipivoxil should | 2 |
adenomatous polyp diagnosed | 2 |
adequate gramnegative activity | 2 |
adjunctive inhaled colistin | 2 |
adjunctive therapy patients | 2 |
adjunctive therapy when | 2 |
administered hours before | 2 |
admitted hospital should | 2 |
adrenal mass ultrasonography | 2 |
adults requesting protection | 2 |
adults risk infection | 3 |
advance directives should | 2 |
advanced anthracyclinesensitive cancer | 2 |
advanced colorectal cancer | 2 |
advanced lung cancer | 2 |
advanced metastatic breast | 3 |
advanced small cell | 2 |
advanced unresectable stage | 2 |
adverse event after | 2 |
aeruginosa other gramnegative | 2 |
aeruginosa recommend against | 2 |
african americans nyha | 2 |
after careful candidate | 2 |
after holding antisecretory | 2 |
after informed discussion | 2 |
after undergoing previous | 3 |
against aminoglycoside monotherapy | 2 |
against cardiotoxicity associated | 2 |
against routine screening | 5 |
against tetanus diphtheria | 3 |
agent active against | 5 |
agent being considered | 2 |
agents active against | 2 |
agents adequate gramnegative | 2 |
agents treatment proven | 2 |
airflow parameter recommended | 2 |
aldosterone antagonists selected | 2 |
aldosterone receptor antagonists | 5 |
alone rather than | 4 |
already being treated | 3 |
also option secondline | 2 |
altered mental status | 3 |
alternative agents adequate | 2 |
alternatives inhibitors firstline | 2 |
ambulatory class symptoms | 3 |
ambulatory unfractionated heparin | 2 |
american academy pediatrics | 4 |
americans nyha class | 2 |
analysis patients clinical | 2 |
anaphylactic reaction chicken | 2 |
anastrozole exemestane letrozole | 2 |
anesthesia should used | 2 |
angiotensin receptorneprilysin inhibitor | 2 |
angiotensinconverting enzyme inhibitor | 2 |
antagonists selected patients | 2 |
anthracycline adjuvant therapy | 2 |
anthracyclinecontaining chemotherapy indicated | 2 |
anthracyclinesensitive cancer m | 2 |
antibiotic active against | 3 |
antibiotic activity against | 3 |
antibiotic in days | 2 |
antibiotic susceptibility testing | 2 |
antibiotics different classes | 2 |
anticoagulation oral such | 2 |
anticoagulation reasonable patients | 2 |
anticoagulation recommended patients | 2 |
antimicrobial resistance being | 2 |
antimicrobial susceptibility testing | 2 |
antimicrobial therapy days | 2 |
aortic valve replacement | 2 |
apparent first unprovoked | 2 |
appropriate information about | 2 |
appropriate initial subsequent | 2 |
appropriately qualified healthcare | 2 |
arbs recommended patients | 2 |
aromatase inhibitors anastrozole | 2 |
arterial blood pressure | 2 |
artery bypass graft | 2 |
artery revascularization coronary | 2 |
ascitic fluid should | 2 |
aspergillus skin soft | 2 |
aspirates biopsies swabs | 2 |
assess fibrinolytic therapy | 2 |
assessment organizational readiness | 2 |
assessment should include | 2 |
associated related macular | 2 |
asymptomatic children aged | 2 |
asymptomatic microscopic hematuria | 2 |
asymptomatic pregnant women | 2 |
attain systolic blood | 2 |
atypical thought obscuring | 2 |
aureus isolates methicillin | 3 |
aware risk factors | 2 |
axis positive scanning | 2 |
barriers education involvement | 2 |
based primarily consensus | 2 |
based upon results | 2 |
basic life support | 3 |
basis risk factors | 2 |
because there data | 2 |
been taking warfarin | 2 |
before surgery continued | 2 |
behavioral interventions promote | 3 |
being considered monotherapy | 2 |
being treated empirically | 7 |
being treated icus | 2 |
beneficial adjunctive therapy | 2 |
best initial treatment | 3 |
best supportive care | 3 |
beta blockers aldosterone | 2 |
beta blockers proven | 2 |
beta blockers should | 2 |
between oral health | 2 |
between patient practitioner | 2 |
biopsy poses substantial | 2 |
biopsy radiographically enlarged | 2 |
biopsy recommended mediastinal | 2 |
biopsy rule metastatic | 2 |
birth after cesarean | 2 |
blockers aldosterone antagonists | 2 |
blockers proven reduce | 2 |
blockers should used | 2 |
blocking drugs recommended | 2 |
blood cell count | 3 |
blood cell transfusion | 2 |
blood lead levels | 3 |
blood pressure controlled | 2 |
blood pressure remains | 2 |
blood pressure should | 2 |
blood test diagnose | 3 |
blood urea nitrogen | 2 |
bone scanning liver | 2 |
branch block type | 2 |
breast cancer being | 2 |
breast cancer surveillance | 2 |
breast conservation surgery | 2 |
bundle branch block | 3 |
calcium channel blockers | 2 |
cancer adenomatous polyp | 2 |
cancer being considered | 2 |
cancer good performance | 2 |
cancer guideline developers | 3 |
cancer m continued | 2 |
cancer should advised | 2 |
cancer staging locoregional | 2 |
candida parapsilosis been | 2 |
candidates chemotherapy m | 2 |
cannot stabilized standard | 2 |
carbapenemresistant pathogen sensitive | 2 |
cardiac troponin testing | 2 |
cardiotoxicity associated conventionaldose | 2 |
cardiovascular risk factors | 3 |
care clinician should | 2 |
care providers should | 2 |
carefully selected patients | 4 |
carer should consulted | 2 |
caused acinetobacter species | 5 |
caused carbapenemresistant pathogen | 2 |
causes segment elevation | 2 |
cd lymphocyte counts | 2 |
cefazolin preferred agents | 2 |
cefazolin preferred treatment | 2 |
cefepime levofloxacin imipenem | 3 |
cell lung cancer | 14 |
cellmediated immunodeficiency immersion | 2 |
cervical ripening induction | 2 |
cesarean delivery should | 2 |
cesarean delivery transverse | 2 |
change clinical status | 2 |
characteristics including time | 2 |
chemotherapy indicated opinion | 2 |
chemotherapy m erlotinib | 2 |
chemotherapy neutropenia severe | 2 |
chest radiograph findings | 2 |
chest radiography indicated | 2 |
chest scan greater | 2 |
child risk developmental | 2 |
children adolescents newly | 2 |
children developmental delay | 2 |
children otitis media | 2 |
choice antibiotic definitive | 2 |
choice should based | 2 |
choice treatment should | 2 |
cholesterol highdensity lipoprotein | 2 |
chronic abdominal pain | 2 |
chronic anticoagulation reasonable | 2 |
chronic cough nonasthmatic | 2 |
chronic cough should | 2 |
chronic hfref out | 2 |
chronic hfref reduce | 3 |
chronic lymphocytic leukemia | 2 |
chronic obstructive pulmonary | 3 |
chronic permanent persistent | 3 |
cisplatinbased combination chemotherapy | 2 |
class ambulatory class | 4 |
class symptoms gdmt | 5 |
client centred care | 2 |
clients should referred | 2 |
clindamycin recommended treatment | 2 |
clinical breast examination | 5 |
clinical characteristics including | 2 |
clinical criteria alone | 5 |
clinical criteria decide | 4 |
clinical grounds out | 2 |
clinical practice guidelines | 4 |
clinical presentation strongly | 2 |
clinical strategy inhibition | 2 |
clinically operable nsclc | 2 |
clinician responsible treatment | 3 |
clinicians considering laboratory | 3 |
clinicians should assess | 3 |
clinicians should inform | 2 |
clinicians should refer | 3 |
clinics officebased practices | 2 |
combination docetaxel capecitabine | 2 |
combination hydralazine isosorbide | 4 |
combination therapy most | 2 |
commissioners should only | 2 |
commonly used fractionation | 2 |
complete blood count | 2 |
complex partial seizures | 2 |
compression placed intraoperatively | 2 |
computed tomography scan | 3 |
concludes evidence insufficient | 7 |
concomitant estrogen therapy | 2 |
confirmed cutaneous disseminated | 2 |
congestive heart failure | 2 |
conjunction evidencebased beta | 2 |
consent should obtained | 2 |
conservation surgery should | 2 |
consideration should given | 2 |
considered acute treatment | 2 |
considered decrease hospitalizations | 2 |
considered high risk | 4 |
considered patients lvef | 3 |
considered persistently symptomatic | 2 |
considered potentially resectable | 2 |
considered secondline subsequent | 2 |
considered treatment option | 2 |
considering laboratory blood | 3 |
contiguous limb leads | 2 |
contiguous precordial leads | 2 |
continued anthracyclinecontaining chemotherapy | 2 |
continued until patient | 2 |
continuous intravenous inotropic | 3 |
continuous positive airway | 2 |
contraindicated reduce morbidity | 4 |
contribute implementation process | 2 |
controlled research study | 2 |
controlled trials comparing | 2 |
cooperative oncology group | 2 |
coronary artery bypass | 2 |
coronary artery disease | 3 |
coronary artery revascularization | 2 |
coronary heart disease | 2 |
coronary syndrome reduced | 2 |
correct deficiencies recommended | 2 |
corticosteroids followed inhaled | 2 |
cost tolerability patient | 2 |
cough asthma should | 2 |
cough nonasthmatic eosinophilic | 2 |
cough secondary sarcoidosis | 2 |
could considered adjuvant | 3 |
count cells mm3 | 3 |
course antimicrobial therapy | 2 |
coverage above agents | 2 |
criteria alone rather | 4 |
criteria decide whether | 4 |
critical aortic stenosis | 2 |
ctfphc concludes there | 3 |
culture exudates skin | 2 |
current prior symptoms | 7 |
current symptoms chronic | 2 |
cutaneous aspirates biopsies | 2 |
cyclophosphamide doxorubicin vincristine | 2 |
dabigatran apixaban rivaroxaban | 2 |
data safety efficacy | 2 |
days post lvef | 3 |
days recommended treatment | 2 |
decide whether initiate | 4 |
decision should made | 2 |
dedication qualified individual | 2 |
deep vein thrombosis | 3 |
dehydration fluid electrolyte | 2 |
delivery transverse incision | 2 |
density lipoprotein cholesterol | 3 |
depressed cardiac output | 2 |
designed controlled research | 2 |
develop plan implementation | 2 |
developers recommend against | 3 |
developers suggest clinicians | 3 |
developing type diabetes | 2 |
device therapy eligible | 2 |
dexrazoxane protect against | 2 |
diabetes admitted hospital | 2 |
diabetic foot infections | 2 |
diagnose epileptic seizures | 3 |
diagnosis acute bronchitis | 2 |
diagnostic evaluation patients | 2 |
diastolic blood pressure | 4 |
diphtheria pertussis they | 2 |
diphtheria tetanus toxoids | 2 |
diphtheria toxoids vaccine | 2 |
direct indirect supportive | 2 |
directives should taken | 2 |
discontinuation antibiotic therapy | 2 |
discussion education reinforce | 2 |
disease cannot stabilized | 2 |
disease patient otherwise | 2 |
disorders should receive | 2 |
distantsite palliative effects | 2 |
diuretics recommended patients | 2 |
docetaxel m2 over | 3 |
documented severe systolic | 2 |
does preclude biopsy | 2 |
done after holding | 2 |
doxorubicin vincristine prednisone | 2 |
doxycycline recommended treatment | 2 |
drug interactions other | 2 |
drugs potentially harmful | 2 |
drugs recommended routine | 2 |
duration nyha class | 5 |
during initial evaluation | 2 |
early repolarization pericarditis | 2 |
eastern cooperative oncology | 2 |
eating disorders should | 2 |
ecog level should | 2 |
education implementation process | 2 |
education involvement members | 2 |
education reinforce importance | 2 |
educational health care | 2 |
effective shortterm treatment | 2 |
effective should considered | 2 |
effects externalbeam radiation | 2 |
efficacy testosterone therapy | 2 |
either alone combination | 3 |
either vancomycin linezolid | 2 |
elevated blood lead | 3 |
elevation early repolarization | 2 |
elevations greater than | 2 |
emergency department immediately | 3 |
emergency tracheal intubation | 2 |
emission tomography scanning | 2 |
empiric coverage above | 2 |
empiric coverage mrsa | 2 |
empiric treatment above | 2 |
empiric treatment includes | 3 |
empiric treatment suspected | 4 |
empirically recommend prescribing | 2 |
endoscopic general surgeon | 2 |
enlarged mediastinal lymph | 2 |
enoxaparin administered hours | 2 |
epilepsy surgery center | 2 |
equal millivolts more | 2 |
equal more contiguous | 2 |
esophageal recording possibly | 2 |
estimated glomerular filtration | 3 |
estrogen therapy cannot | 2 |
evaluation patients advanced | 2 |
evaluation patients presenting | 2 |
even they history | 2 |
event after undergoing | 2 |
event cardioembolic source | 2 |
every three weeks | 3 |
every three years | 2 |
evidence insufficient recommend | 7 |
evidence recommend treatment | 2 |
evidence support refute | 3 |
evidence supports dexrazoxane | 2 |
evidence time make | 2 |
evidencebased beta blockers | 3 |
except palliation patients | 2 |
exemestane letrozole in | 2 |
expectation meaningful survival | 2 |
experienced adverse event | 2 |
external beam radiation | 2 |
external beam radiotherapy | 2 |
external radiation therapy | 2 |
exudates skin lesions | 2 |
factor antimicrobial resistance | 2 |
factor cardioembolic stroke | 3 |
factors antimicrobial resistance | 2 |
factors cost tolerability | 2 |
factors guideline developers | 2 |
family members appropriate | 2 |
fasting lipid profile | 2 |
features infarction causes | 2 |
fewer than seven | 2 |
fibrinolytic therapy patients | 3 |
filtration rate m | 2 |
finding isolated adrenal | 2 |
first line treatment | 2 |
first unprovoked seizures | 2 |
firstline therapy patients | 2 |
flexible sigmoidoscopy every | 2 |
fluid electrolyte imbalance | 3 |
folic acid supplementation | 2 |
followed inhaled corticosteroids | 2 |
following lumbar fusion | 2 |
following recommendations based | 3 |
following risk factor | 2 |
force concludes evidence | 2 |
formal nutrition assessment | 2 |
found chest scan | 2 |
fully ambulatory unfractionated | 2 |
fully into account | 2 |
functional abdominal pain | 2 |
further assessment management | 2 |
fusion surgery recommended | 2 |
gastroesophageal reflux disease | 2 |
gastrointestinal side effects | 2 |
gdmt device therapy | 2 |
gdmt reasonable expectation | 2 |
gdmt titrated attain | 2 |
general surgeon should | 2 |
geriatric depression scale | 2 |
gestational diabetes mellitus | 2 |
glomerular filtration rate | 4 |
good performance status | 7 |
gram stain culture | 6 |
gramnegative activity available | 2 |
gramnegative isolates resistant | 2 |
granulocyte colonystimulating factor | 2 |
greater than equal | 4 |
greater than shortest | 2 |
grounds out prior | 2 |
guide discontinuation antibiotic | 2 |
guideline developers recommend | 14 |
guideline developers suggest | 10 |
harmful patients hfref | 3 |
health care professionals | 3 |
health care providers | 3 |
health maintenance exam | 2 |
healthcare professional expertise | 2 |
healthcare professional further | 2 |
heart rate beats | 2 |
heparin administered hours | 2 |
hfref cannot given | 2 |
hfref current prior | 2 |
hfref except palliation | 2 |
hfref nyha class | 2 |
hfref out prior | 2 |
hfref reduce morbidity | 3 |
hfref unless contraindicated | 2 |
high risk death | 2 |
high risk developing | 2 |
high risk mortality | 3 |
high risk recurrent | 2 |
highdensity lipoprotein cholesterol | 4 |
highrisk chronic lymphocytic | 2 |
history acute coronary | 3 |
history cancer guideline | 3 |
history physical exam | 2 |
history physical examination | 3 |
history should obtained | 2 |
home cardiorespiratory monitoring | 3 |
hormonal therapies other | 2 |
hormone replacement therapy | 2 |
hospital satellite unit | 2 |
hospitals clinics officebased | 2 |
hour every three | 3 |
hours before surgery | 3 |
hours guideline developers | 2 |
hours symptom onset | 3 |
human chorionic gonadotropin | 2 |
human immunodeficiency virus | 8 |
hydralazine isosorbide dinitrate | 4 |
hyperbaric oxygen therapy | 2 |
hyperfractionated accelerated radiation | 2 |
hyperkalemia renal insufficiency | 2 |
hypertension diabetes mellitus | 2 |
hypertrophy incomplete bundle | 2 |
identified clients should | 2 |
iiia lung cancer | 2 |
imipenem meropenem oxacillin | 2 |
immersion injuries animal | 2 |
immunodeficiency immersion injuries | 2 |
immunodeficiency virus infected | 2 |
implementation includes assessment | 2 |
implementation process ongoing | 2 |
importance best practices | 2 |
improve functional status | 2 |
improve live birth | 2 |
improve quality life | 2 |
improves survival over | 2 |
improving quality care | 2 |
in days after | 2 |
in hours symptom | 3 |
in their licensed | 3 |
inactivated influenza vaccine | 2 |
incidence diabetes progression | 2 |
incision drainage should | 2 |
includes assessment organizational | 2 |
includes coverage mssa | 3 |
including agent active | 2 |
including piperacillintazobactam cefepime | 3 |
including time international | 2 |
incomplete bundle branch | 2 |
increased intracranial pressure | 2 |
increased risk syphilis | 2 |
indicated opinion treating | 2 |
indicated suggest regimen | 3 |
indications recommended options | 2 |
indirect supportive function | 2 |
individual clinician responsible | 3 |
individual provide support | 2 |
individual'advocate carer should | 2 |
individualized basis risk | 2 |
individuals out symptoms | 2 |
infarction causes segment | 2 |
infarction presenting in | 2 |
infected patients cd | 2 |
infected substance users | 3 |
infection prior intravenous | 2 |
infection sufficient impair | 2 |
infections should treated | 6 |
inflamed epidermoid cysts | 2 |
informed discussion between | 2 |
infused positive inotropic | 2 |
inhibition reninangiotensin system | 2 |
inhibitor should administered | 2 |
inhibitors anastrozole exemestane | 2 |
inhibitors firstline therapy | 2 |
inhibitors recommended patients | 2 |
inhibitors should used | 2 |
initial subsequent treatment | 2 |
initiate antibiotic therapy | 4 |
injuries animal bites | 2 |
inotropic drugs potentially | 2 |
inotropic support reasonable | 2 |
insufficient data support | 2 |
insufficient evidence recommend | 6 |
insufficient evidence regarding | 2 |
insufficient evidence support | 4 |
insufficient evidence supporting | 2 |
insufficient evidence time | 3 |
insufficient recommend against | 7 |
intensive care unit | 4 |
interactions other clinical | 2 |
intermediate highrisk chronic | 2 |
international normalized ratio | 4 |
interpretation serum human | 2 |
interval between oral | 2 |
interventions promote sustained | 3 |
into account individual'advocate | 2 |
intracranial pressure significant | 2 |
intraoperatively continued until | 2 |
intraoral devices appropriate | 2 |
intravenous antibiotic in | 2 |
intravenous inotropic support | 4 |
intravenous loop diuretics | 2 |
invasive hemodynamic monitoring | 3 |
ischemic heart disease | 2 |
isolate susceptible rather | 2 |
isolated adrenal mass | 2 |
isolates methicillin resistant | 3 |
isolates resistant agent | 2 |
isosorbide dinitrate recommended | 2 |
isosorbide dinitrate useful | 2 |
jointly individual clinician | 3 |
jugular venous pressure | 2 |
laar active ingredient | 2 |
laboratory blood test | 3 |
lacking features infarction | 2 |
laparoscopic open surgery | 2 |
laparoscopic surgery recommended | 2 |
last five years | 2 |
later than years | 2 |
lbbb duration nyha | 2 |
lbbb pattern duration | 4 |
le brain radiotherapy | 3 |
lead levels asymptomatic | 3 |
leads greater than | 2 |
leads lacking features | 2 |
least every three | 2 |
left atrial pressure | 2 |
left atypical thought | 2 |
left ventricular hypertrophy | 2 |
lesions impetigo ecthyma | 2 |
lesions should include | 2 |
less than laar | 2 |
less than weeks | 2 |
less than years | 4 |
levels asymptomatic children | 2 |
levels renal function | 2 |
levofloxacin imipenem meropenem | 3 |
licensed indications recommended | 2 |
life support training | 2 |
limb leads greater | 2 |
limitedstage small cell | 2 |
linezolid rather than | 2 |
lipid formulation amphotericin | 3 |
lipoprotein cholesterol highdensity | 2 |
live birth rate | 2 |
liver biopsy poses | 2 |
liver enzymeinducing antibiotics | 3 |
liver function tests | 3 |
liver ultrasonography chest | 3 |
local poison center | 2 |
locally advanced metastatic | 4 |
locally advanced unresectable | 2 |
longterm infused positive | 2 |
loop diuretic therapy | 2 |
loss obese adults | 2 |
lumbar fusion surgery | 2 |
lung cancer good | 2 |
lung cancer should | 3 |
lung cancer staging | 2 |
lvef sinus rhythm | 4 |
lymph nodes found | 2 |
lymphocytic leukemia fludarabine | 2 |
m continued anthracyclinecontaining | 2 |
m erlotinib available | 2 |
m liver biopsy | 2 |
m there evidence | 2 |
m2 over hour | 3 |
made after informed | 2 |
made jointly individual | 3 |
magnetic resonance imaging | 9 |
maintain systemic perfusion | 2 |
makers commissioners should | 2 |
malignancy chemotherapy neutropenia | 2 |
mammography clinical breast | 3 |
management comorbid conditions | 2 |
management recommendations assess | 2 |
mass ultrasonography scan | 2 |
media effusion should | 2 |
mediastinal lymph nodes | 2 |
mediastinal node involvement | 2 |
medical therapy reasonable | 2 |
mental health problems | 2 |
mental health professionals | 2 |
meropenem oxacillin nafcillin | 2 |
metastatic breast cancer | 6 |
metastatic disease patient | 2 |
might considered decrease | 2 |
might reduce risk | 2 |
millivolts more contiguous | 2 |
mitral valve repair | 2 |
months after initiation | 2 |
morbidity mortality patients | 3 |
more common causes | 2 |
more contiguous limb | 2 |
more contiguous precordial | 2 |
more than hours | 2 |
more thorough assessment | 2 |
mortality selected patients | 2 |
mortality suggest prescribing | 3 |
most women previous | 2 |
mssa necessary empiric | 4 |
mucor rhizopus infections | 2 |
muscle strength function | 2 |
myocardial infarction presenting | 2 |
myocardial perfusion spect | 2 |
nafcillin cefazolin preferred | 4 |
natriuretic peptide biomarkers | 2 |
necessary empiric coverage | 2 |
necessary empiric treatment | 2 |
needed education implementation | 2 |
negative scanning does | 2 |
neuroimaging should considered | 2 |
neurologic examination focal | 2 |
neuromuscular blocking agents | 3 |
neutropenia severe cellmediated | 2 |
nodes found chest | 2 |
nonasthmatic eosinophilic bronchitis | 3 |
noninvasive sampling semiquantitative | 2 |
nonsteroidal antiinflammatory drugs | 3 |
normalized ratio therapeutic | 2 |
nsclc biopsy recommended | 2 |
nurses practice settings | 2 |
nurses will advocate | 2 |
nursing best practice | 2 |
nutrition training practices | 2 |
nutritional supplements treatment | 2 |
nyha class ambulatory | 4 |
nyha class lvef | 4 |
nyha class symptoms | 5 |
obscuring segment analysis | 2 |
obstructive pulmonary disease | 3 |
occur between patient | 2 |
offered trial labor | 2 |
once daily days | 2 |
ongoing opportunities discussion | 2 |
only patients following | 2 |
only polymyxins recommend | 2 |
only polymyxins suggest | 2 |
onset reveals elevations | 2 |
open surgery colon | 2 |
operable nsclc biopsy | 2 |
opinion treating physician | 2 |
opportunities discussion education | 2 |
option after failure | 2 |
option secondline therapy | 2 |
oral health reviews | 2 |
oral such warfarin | 3 |
organizational readiness barriers | 2 |
original guideline document | 5 |
other airflow parameter | 2 |
other clinical characteristics | 2 |
other gramnegative bacilli | 2 |
other risk factors | 3 |
other than correct | 2 |
otherwise considered potentially | 2 |
otitis media effusion | 4 |
out additional risk | 2 |
out concomitant estrogen | 2 |
out prior histological | 2 |
out prior thromboembolic | 2 |
out risk factors | 2 |
out symptoms history | 2 |
outcome following lumbar | 2 |
outside clinical trial | 4 |
over best supportive | 2 |
over first hours | 2 |
over hour every | 3 |
over month period | 2 |
over standard radiotherapy | 3 |
oxacillin nafcillin cefazolin | 4 |
palliation patients stage | 2 |
palliative effects externalbeam | 2 |
parapsilosis been isolated | 2 |
parenttraining education programmes | 2 |
paroxysmal out additional | 2 |
paroxysmal should individualized | 2 |
part baseline staging | 3 |
part properly designed | 2 |
pathogen sensitive only | 2 |
pathological stage tumours | 2 |
patient been taking | 2 |
patient fully ambulatory | 2 |
patient greater than | 2 |
patient management recommendations | 2 |
patient otherwise considered | 2 |
patient preference potential | 2 |
patient should occur | 2 |
patients acute cough | 2 |
patients advanced anthracyclinesensitive | 2 |
patients advanced lung | 2 |
patients advanced small | 2 |
patients aeruginosa recommend | 3 |
patients being treated | 8 |
patients candidates chemotherapy | 2 |
patients carers should | 2 |
patients caused acinetobacter | 5 |
patients caused carbapenemresistant | 2 |
patients cd lymphocyte | 2 |
patients chronic cough | 5 |
patients chronic hfref | 4 |
patients chronic permanent | 3 |
patients clinical presentation | 2 |
patients cough secondary | 2 |
patients critical aortic | 2 |
patients cryptogenic stroke | 2 |
patients current prior | 6 |
patients diabetes admitted | 2 |
patients eastern cooperative | 2 |
patients following risk | 2 |
patients hfref current | 2 |
patients hfref except | 2 |
patients high risk | 5 |
patients increased risk | 2 |
patients intermediate highrisk | 2 |
patients intermediate risk | 2 |
patients less than | 2 |
patients locally advanced | 3 |
patients lumbar stenosis | 2 |
patients lung cancer | 2 |
patients lvef sinus | 4 |
patients m other | 2 |
patients malignancy chemotherapy | 2 |
patients nyha class | 7 |
patients out risk | 2 |
patients previously received | 2 |
patients prior current | 2 |
patients recent remote | 3 |
patients recommend course | 2 |
patients recommended patients | 2 |
patients reduced prevent | 2 |
patients should desensitized | 2 |
patients should instructed | 2 |
patients should monitored | 2 |
patients should offered | 2 |
patients should receive | 3 |
patients should screened | 2 |
patients stage despite | 2 |
patients stage disease | 2 |
patients stage hfref | 2 |
patients stage refractory | 2 |
patients suggest antibiotic | 2 |
patients suspected confirmed | 2 |
patients suspected recommend | 4 |
patients suspected suggest | 4 |
patients symptoms suggestive | 3 |
patients their families | 2 |
patients undergoing gynecologic | 3 |
patients undergone resection | 2 |
patients unless contraindicated | 2 |
pattern duration nyha | 3 |
pediatric cancer center | 2 |
pediatricians should promote | 2 |
pediatricians should support | 2 |
perform transvaginal ultrasound | 2 |
performed every years | 2 |
pericarditis left ventricular | 2 |
perioperative visual loss | 2 |
permanent persistent paroxysmal | 5 |
persistent paroxysmal out | 2 |
persistent paroxysmal should | 2 |
persistently symptomatic patients | 2 |
persons increased risk | 3 |
persons should receive | 2 |
physical activity part | 2 |
physical examination should | 2 |
piperacillintazobactam cefepime levofloxacin | 3 |
placed intraoperatively continued | 2 |
plan implementation includes | 2 |
plus clinical criteria | 4 |
pneumatic compression placed | 2 |
policy makers commissioners | 2 |
polymyxins recommend intravenous | 2 |
polymyxins suggest adjunctive | 2 |
poses substantial risk | 2 |
positive airway pressure | 2 |
positive inotropic drugs | 2 |
positive scanning negative | 2 |
positron emission tomography | 2 |
possible advance directives | 2 |
postoperative pulmonary complications | 3 |
postoperatively until discharge | 2 |
potential drug interactions | 2 |
potential side effects | 2 |
potential toxicity mitoxantrone | 2 |
potentially harmful patients | 3 |
potentially malicious administration | 2 |
practice settings should | 2 |
practitioners policy makers | 2 |
practitioners should follow | 2 |
preclude biopsy radiographically | 2 |
precordial leads lacking | 2 |
predict outcome following | 2 |
predictive outcome prognosis | 2 |
preference potential drug | 2 |
preferred agents treatment | 2 |
preferred treatment proven | 2 |
premature rupture membranes | 2 |
prescribed gdmt titrated | 2 |
prescribing antibiotic activity | 3 |
presence lung cancer | 3 |
presentation strongly suggestive | 2 |
presenting in hours | 3 |
pressure should controlled | 2 |
prevalence mrsa known | 2 |
prevent symptomatic even | 2 |
preventive services task | 4 |
previous cesarean delivery | 3 |
previous liver biopsy | 2 |
previously received anthracycline | 2 |
primarily consensus expert | 2 |
primary care clinician | 3 |
primary care physician | 2 |
primary care provider | 2 |
prior current symptoms | 2 |
prior histological classification | 2 |
prior intravenous antibiotic | 2 |
prior symptoms hfref | 5 |
prior thromboembolic event | 2 |
procedural sedation analgesia | 2 |
procedure endoscopic surgeon | 2 |
process ongoing opportunities | 2 |
professional further assessment | 2 |
promote physical activity | 2 |
promote sustained weight | 3 |
properly designed controlled | 2 |
prosthetic heart valves | 2 |
protect against cardiotoxicity | 2 |
protocol recommended orthopaedic | 2 |
proton pump inhibitor | 2 |
proven mssa necessary | 4 |
proven reduce mortality | 2 |
provide support needed | 2 |
psoriasis responded adequately | 2 |
published clinical practice | 2 |
pulmonary complications should | 2 |
pump inhibitor therapy | 2 |
qualified healthcare professional | 2 |
qualified individual provide | 2 |
quality improvement programs | 2 |
radiograph findings normal | 2 |
radiographically enlarged mediastinal | 2 |
randomised controlled trials | 2 |
randomized controlled trial | 3 |
randomized controlled trials | 4 |
randomized phase study | 2 |
range patient been | 2 |
rate m potassium | 2 |
rather than using | 4 |
ratio therapeutic range | 2 |
readiness barriers education | 2 |
reasonable adjunctive therapy | 2 |
reasonable expectation meaningful | 2 |
reasonable patients chronic | 2 |
reasonable patients critical | 2 |
reasonable patients presenting | 2 |
reasonable treatment option | 3 |
reasonable typical cases | 2 |
receive dose tdap | 2 |
receive single dose | 4 |
received anthracycline adjuvant | 2 |
recent remote history | 3 |
receptor antagonists recommended | 2 |
receptorneprilysin inhibitor should | 2 |
recommend against aminoglycoside | 2 |
recommend against routine | 4 |
recommend against single | 2 |
recommend choice antibiotic | 2 |
recommend course antimicrobial | 2 |
recommend using clinical | 3 |
recommendation practitioners policy | 2 |
recommendation very quality | 3 |
recommendations assess fibrinolytic | 2 |
recommendations based primarily | 2 |
recommendationsthere insufficient evidence | 3 |
recommended because been | 2 |
recommended child risk | 2 |
recommended children first | 2 |
recommended mediastinal lymph | 2 |
recommended orthopaedic surgeon | 2 |
recommended outside clinical | 2 |
recommended patients apparent | 3 |
recommended patients chronic | 5 |
recommended patients current | 4 |
recommended patients hfref | 6 |
recommended patients high | 2 |
recommended patients nyha | 3 |
recommended primary prevention | 2 |
recommended reduce morbidity | 2 |
recommended routine breast | 2 |
recommended routine treatment | 2 |
recommended safe effective | 2 |
recommended treatment option | 2 |
recommends against routine | 4 |
recommends clinicians screen | 3 |
recording possibly indicated | 2 |
recurrent pregnancy loss | 2 |
reduce congestive symptoms | 2 |
reduce incidence diabetes | 2 |
reduce morbidity mortality | 13 |
reduce risk transmitting | 2 |
reduce total mortality | 2 |
reduced prevent symptomatic | 2 |
referred emergency department | 5 |
referred secondary care | 2 |
referred trained healthcare | 2 |
regimen including piperacillintazobactam | 3 |
regular physical activity | 2 |
reinforce importance best | 2 |
related insufficient evidence | 2 |
related macular degeneration | 3 |
remote history acute | 3 |
repolarization pericarditis left | 2 |
requesting protection infection | 2 |
requires biopsy rule | 2 |
research study determine | 2 |
resistance being treated | 2 |
resistant agent being | 2 |
resonance imaging recommended | 2 |
respiratory rate breaths | 2 |
responded adequately weeks | 2 |
results antibiotic susceptibility | 2 |
results antimicrobial susceptibility | 2 |
revascularization coronary artery | 2 |
reveals elevations greater | 2 |
rhizopus infections should | 2 |
rhythm lbbb duration | 2 |
rhythm lbbb pattern | 3 |
right left atypical | 2 |
risk coronary heart | 2 |
risk developing type | 2 |
risk development progression | 2 |
risk developmental difficulties | 2 |
risk factor antimicrobial | 2 |
risk factor cardioembolic | 3 |
risk factors antimicrobial | 2 |
risk factors cost | 2 |
risk factors guideline | 2 |
risk factors mrsa | 2 |
risk factors such | 2 |
risk mortality suggest | 3 |
risk postoperative pulmonary | 3 |
risk syphilis infection | 2 |
risk transmitting pertussis | 2 |
risky behavior should | 2 |
routine breast cancer | 2 |
routine evaluation patients | 2 |
routine screening elevated | 3 |
rule metastatic disease | 2 |
safety efficacy testosterone | 2 |
sampling semiquantitative cultures | 2 |
scan greater than | 2 |
scan requires biopsy | 2 |
scan scan requires | 2 |
scanning does preclude | 2 |
scanning liver ultrasonography | 2 |
scanning negative scanning | 2 |
schemes promote physical | 2 |
schoolbased mental health | 2 |
screen presence lung | 3 |
screening children developmental | 2 |
screening elevated blood | 3 |
screening questions into | 2 |
screening treatment asymptomatic | 2 |
secondary prevention drawal | 2 |
segment analysis patients | 2 |
segment elevation early | 2 |
selected patients recommended | 2 |
selected patients stage | 2 |
selected symptomatic patients | 2 |
selection anticoagulant agent | 2 |
selective serotonin reuptake | 2 |
sensitive only polymyxins | 4 |
septic shock high | 2 |
serotonin reuptake inhibitors | 2 |
serum human chorionic | 2 |
services task force | 4 |
seven days after | 2 |
severe cellmediated immunodeficiency | 2 |
severe systolic dysfunction | 3 |
shock high risk | 2 |
shortest transverse axis | 2 |
shortterm treatment infantile | 2 |
should administered patients | 3 |
should also given | 2 |
should begin approximately | 2 |
should considered acute | 2 |
should considered children | 2 |
should considered only | 2 |
should considered patients | 9 |
should considered reduce | 2 |
should considered risk | 2 |
should considered treatment | 2 |
should considered useful | 2 |
should controlled accordance | 2 |
should counseled about | 2 |
should counseled their | 2 |
should discussed patient | 2 |
should individualized basis | 3 |
should made after | 3 |
should made available | 2 |
should made jointly | 3 |
should occur between | 2 |
should only endorse | 2 |
should performed in | 2 |
should performed patients | 3 |
should prescribed gdmt | 2 |
should receive appropriate | 2 |
should receive chemotherapy | 2 |
should receive doses | 2 |
should receive single | 3 |
should refer patients | 2 |
should referred emergency | 5 |
should referred multidisciplinary | 2 |
should referred secondary | 2 |
should referred trained | 2 |
should referred transplant | 2 |
should reserved patients | 3 |
should take into | 5 |
should taken fully | 2 |
should used because | 2 |
should used patients | 6 |
should used people | 2 |
should used prevent | 2 |
should used treatment | 3 |
should used when | 2 |
side effects longterm | 2 |
sideeffect profiles individual | 2 |
sigmoidoscopy every years | 2 |
significant change clinical | 2 |
significant maternal fetal | 2 |
significantly depressed cardiac | 2 |
signs increased intracranial | 2 |
single dose tdap | 4 |
singleagent docetaxel m2 | 2 |
sinus rhythm lbbb | 5 |
situations informed discussion | 2 |
skin lesions impetigo | 2 |
skin lesions should | 2 |
skin soft tissue | 6 |
small cell lung | 14 |
soft tissue infections | 5 |
some specialists recommend | 2 |
species sensitive only | 3 |
specific risk factor | 2 |
spinal cord injury | 2 |
stabilized standard medical | 2 |
stage disease cannot | 2 |
stage iiia lung | 2 |
stage small cell | 3 |
staging distant metastatic | 2 |
stain culture exudates | 2 |
standard medical treatment | 2 |
standard radiotherapy fractions | 2 |
statins beneficial adjunctive | 2 |
strategy inhibition reninangiotensin | 2 |
strong stand against | 2 |
strongly recommends clinicians | 2 |
study determine effectiveness | 2 |
study done after | 3 |
subsequent treatment waldenstrom'macroglobulinaemia | 2 |
sudden cardiac death | 3 |
sufficient impair quality | 2 |
suggest adjunctive inhaled | 2 |
suggest including agent | 2 |
suggest prescribing antibiotic | 3 |
suggest regimen including | 3 |
suggestive acute myocardial | 2 |
supplementation reasonable adjunctive | 2 |
supplements treatment recommended | 2 |
support needed education | 2 |
supports dexrazoxane protect | 2 |
suppurative airways disease | 2 |
surgery colon cancer | 2 |
surgery continued postoperatively | 2 |
surgical site infections | 3 |
survival good functional | 2 |
survival over standard | 2 |
susceptibility testing known | 2 |
susceptible rather than | 2 |
suspected confirmed cutaneous | 2 |
suspected only patients | 2 |
suspected patients out | 2 |
suspected recommend using | 3 |
suspected selfharm victims | 2 |
suspected suggest avoiding | 2 |
suspected suggest using | 2 |
suspicious lung cancer | 2 |
sustained weight loss | 4 |
symptom onset reveals | 3 |
symptomatic even they | 2 |
symptomatic patients hfref | 2 |
symptoms chronic hfref | 2 |
symptoms history cancer | 3 |
symptoms suggestive acute | 2 |
syndrome cannot recommended | 2 |
systemic antimicrobial therapy | 2 |
systemic perfusion preserve | 2 |
systemic signs infection | 4 |
systolic blood pressure | 4 |
table original guideline | 2 |
take into account | 6 |
taken fully into | 2 |
taking into account | 2 |
task force concludes | 2 |
task force recommends | 5 |
task force suggests | 2 |
team members should | 2 |
test diagnose epileptic | 3 |
testosterone therapy out | 2 |
testosterone therapy women | 2 |
tetanus diphtheria pertussis | 4 |
tetanus diphtheria toxoids | 3 |
tetanus toxoids acellular | 2 |
than correct deficiencies | 2 |
than equal millivolts | 2 |
than equal more | 2 |
than laar active | 2 |
than shortest transverse | 2 |
than years should | 2 |
their licensed indications | 4 |
therapeutic range patient | 2 |
therapies other than | 2 |
therapy based upon | 2 |
therapy cannot recommended | 2 |
therapy indicated patients | 2 |
therapy oral corticosteroids | 2 |
therapy out concomitant | 2 |
therapy patients advanced | 2 |
therapy patients symptoms | 3 |
therapy rather than | 2 |
therapy recommended primary | 2 |
therapy should considered | 3 |
therapy when prescribed | 2 |
therapy women using | 2 |
there current recommendations | 2 |
there data safety | 2 |
there insufficient data | 4 |
there insufficient evidence | 14 |
thorough history physical | 3 |
thought obscuring segment | 2 |
three four months | 2 |
thromboembolic event cardioembolic | 2 |
thyroid function tests | 2 |
time international normalized | 2 |
tissue infections should | 4 |
titrated attain systolic | 2 |
tolerability patient preference | 2 |
tomography scanning recommended | 2 |
tool predict outcome | 2 |
total mortality selected | 2 |
toxoids acellular pertussis | 2 |
trained healthcare professional | 2 |
transient ischemic attack | 2 |
transplantation procedure choice | 2 |
transverse axis positive | 2 |
transverse incision candidates | 2 |
treated empirically recommend | 3 |
treatment above agents | 2 |
treatment asymptomatic bacteriuria | 2 |
treatment choice should | 2 |
treatment early oestrogenreceptorpositive | 2 |
treatment includes coverage | 3 |
treatment infantile spasms | 3 |
treatment inhaled corticosteroids | 2 |
treatment option after | 2 |
treatment option patients | 4 |
treatment postherpetic neuralgia | 2 |
treatment proven mssa | 4 |
treatment recommended patients | 2 |
treatment should considered | 3 |
treatment should made | 3 |
treatment should monitored | 2 |
treatment suspected only | 2 |
treatment suspected patients | 2 |
trivalent inactivated influenza | 2 |
ultrafiltration considered patients | 2 |
ultrasonography chest radiography | 3 |
ultrasonography scan scan | 2 |
undergoing gynecologic surgery | 3 |
undergoing previous liver | 2 |
undergoing transplantation procedure | 2 |
undergone breast conservation | 2 |
unfractionated heparin administered | 2 |
unless contraindicated reduce | 5 |
unresectable stage small | 2 |
until patient fully | 2 |
upon results antimicrobial | 2 |
urea nitrogen creatinine | 2 |
urinary tract infection | 3 |
urinary tract infections | 2 |
used fractionation schedules | 2 |
used patients reduced | 2 |
used prevent symptomatic | 2 |
useful patients lvef | 3 |
using clinical criteria | 4 |
using concomitant estrogen | 2 |
using validated tool | 2 |
uspstf concludes evidence | 5 |
uspstf recommends against | 4 |
uspstf strongly recommends | 2 |
vaginal birth after | 2 |
vancomycin linezolid rather | 2 |
vancomycin plus either | 2 |
venous thromboembolism prophylaxis | 2 |
ventricular hypertrophy incomplete | 2 |
very quality evidence | 3 |
viable myocardium present | 2 |
warfarin dabigatran apixaban | 2 |
weak recommendation very | 2 |
weight loss obese | 2 |
weight loss should | 2 |
what give hospital | 2 |
when empiric treatment | 3 |
when indicated should | 2 |
when prescribed solely | 2 |
whether direct indirect | 2 |
whether initiate antibiotic | 4 |
white blood cell | 2 |
will advocate clients | 2 |
will contribute implementation | 2 |
women high risk | 2 |
women metastatic breast | 2 |
women pathological stage | 2 |
women pcos unknown | 2 |
women planning pregnancy | 2 |
women previous cesarean | 3 |
women recurrent miscarriage | 2 |
women should advised | 2 |
women using concomitant | 2 |
year life expectancy | 2 |
years every years | 2 |
years should receive | 3 |
york heart association | 2 |
younger than years | 2 |